Intraperitoneal Bevacizumab (Bev) for Control of Malignant Ascites Due to Advanced-Stage Gastrointestinal Cancers (Gi): a Multicenter Double-Blind, Placebo (Pl)-Controlled, Randomized Phase Ii Study. Aio Sup-0108Karin Jordan, S. Hegewisch-Becker, C. Gog et al.|Annals of Oncology|2014Cited by 0